This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Leela Barham and Tim Wilsdon discuss the potential impact that value-based pricing (VBP) may have in the UK and the broader implications for developing international models of Health Technology Assessment (HTA). The article can be found here:
While both CAR-T cell therapies and bispecific antibodies have experienced rapid growth in recent years, new analysis by CRA’s Chris Nüesch suggests that the...
This article, co-authored by CRA’s Will Foster and Juliette Richards, explores how advances in artificial intelligence (AI), data collection, and connected...
CRA is a proud sponsor of the event for market access, reimbursement, and government policy experts. Ashley Fraser presents on “MFN – Implications in...
CRA is a proud sponsor of the event. Josh Sherman is a panelist during the session titled “Global antitrust trends reshaping the life sciences market”...
